N4P vs. CEL, HELD, HLN, BXP, HIK, HCM, INDV, AMYT, APH, and AGY
Should you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Celadon Pharmaceuticals (CEL), Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), and Allergy Therapeutics (AGY). These companies are all part of the "drug manufacturers - specialty & generic" industry.
N4 Pharma vs.
Celadon Pharmaceuticals (LON:CEL) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.
In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled N4 Pharma'saverage media sentiment score.
Celadon Pharmaceuticals has a net margin of -4,024.62% compared to N4 Pharma's net margin of -18,399.86%. N4 Pharma's return on equity of -90.68% beat Celadon Pharmaceuticals' return on equity.
N4 Pharma has lower revenue, but higher earnings than Celadon Pharmaceuticals. N4 Pharma is trading at a lower price-to-earnings ratio than Celadon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Celadon Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, N4 Pharma has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500.
N4 Pharma received 99 more outperform votes than Celadon Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Celadon Pharmaceuticals an outperform vote while only 65.61% of users gave N4 Pharma an outperform vote.
10.7% of Celadon Pharmaceuticals shares are owned by institutional investors. 65.1% of Celadon Pharmaceuticals shares are owned by company insiders. Comparatively, 18.0% of N4 Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Celadon Pharmaceuticals beats N4 Pharma on 8 of the 13 factors compared between the two stocks.
Get N4 Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
N4 Pharma Competitors List
Related Companies and Tools
This page (LON:N4P) was last updated on 4/24/2025 by MarketBeat.com Staff